Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study

A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis

(2020) Max Schlueter et al.   Expert Review of Pharmacoeconomics & Outcomes Research

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib

(2019) Paweł Kawalec et al.   Therapeutics and Clinical Risk Management

Baricitinib: A Review in Rheumatoid Arthritis

(2018) Zaina T. Al-Salama et al.   DRUGS

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Clinical significance of Janus Kinase inhibitor selectivity

(2018) Ernest H Choy   RHEUMATOLOGY

Inflammatory responses and inflammation-associated diseases in organs

(2017) Linlin Chen et al.   Oncotarget

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

(2016) Shingo Nakayamada et al.   BIODRUGS

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Selective JAK inhibitors in development for rheumatoid arthritis

(2014) Peter Norman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS